Unique vascular protective properties of natural products: supplements or future main-line drugs with significant anti-atherosclerotic potential?
Tóm tắt
Natural health products (NHP) which include minerals, vitamins and herbal remedies are not generally considered by medical practitioners as conventional medicines and as such are not frequently prescribed by health centre’s as either main-line or supplemental treatments. In the field of cardiovascular medicine, studies have shown that typically, less than half of patients suffering from coronary syndromes chose to take any form of NHP supplement and these products are rarely recommended by their medical practitioner. Vascular/endothelial cell damage is a key instigator of coronary arterial plaque development which often culminates in thrombosis and myocardial infarction (MI). Current treatment for patients known to be at risk of primary or secondary (MI) includes lipid lowering statins, anti-clotting agents (e.g. tissue plasminogen activator; tPA) and drugs for stabilization of blood pressure such as beta-blockers. However, evidence has been building which suggests that components of at least several NHP (e.g. aged garlic extract (AGExt), resveratrol and green tea extracts (GTE)) may have significant vascular protective effects through reduction of oxidative stress, lowering of blood pressure, reduction in platelet aggregation, vasodilation and inhibition of abnormal angiogenesis. Therefore, in this review we will discuss in detail the potential of these substances (chosen on the basis of their potency and complimentarity) as anti-atherosclerotic agents and the justification for their consideration as main-line additional supplements or prescriptions.
Tài liệu tham khảo
Santos MG, Pegoraro M, Sandrini F, et al: Risk factors for the development of atherosclerosis in childhood and adolescence. Arq Bras Cardiol. 2008, 90: 276-283.
Marroquin OC, Kip KE, Mulukutla SR, et al: Inflammation, endothelial cell activation and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. Am Heart J. 2005, 150: 109-115. 10.1016/j.ahj.2004.08.003.
Stary HC, Chandler AB, Glagov S, et al: A definition of initial fatty streak and intermediate lesions of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis. Circulation. 1994, 89: 2462-2478. 10.1161/01.CIR.89.5.2462.
Sitia S, Tomasoni L, Atzeni F, et al: From endothelial dysfunction to atherosclerosis. Autoimmun Rev. 2010, 9: 830-834. 10.1016/j.autrev.2010.07.016.
Tousoulis D, Koutsogiannis M, Papageorgiou N, et al: Endothelial dysfunction: potential clinical applications. Minerva Med. 2010, 101: 271-284.
Slevin M, Turu MM, Rovira N, et al: Identification of a ‘snapshot’ of co-expressed angiogenic markers in laser-dissected vessels from unstable carotid plaques with targeted arrays. J Vasc Res. 2010, 47: 323-335. 10.1159/000265566.
Slevin M, Krupinski J, Badimon L: Controlling the angiogenic switch in developing atherosclerotic plaques: possible targets for therapeutic intervention. J Angiogenesis Res. 2009, 21 (1): 4-
Hulsmans M, Holvoet P: The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med. 2010, 14: 70-78. 10.1111/j.1582-4934.2009.00978.x.
Arora S, Vaishya R, Dabla PK, et al: NAD(P)H oxidases in coronary artery disease. Adv Clin Chem. 2010, 50: 65-86.
Holvoet P: Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg. 2008, 70: 193-219.
Jandeleit-Dahm K, Cooper ME: The role of AGEs in cardiovasculr disease. Curr Pharm Des. 2008, 14: 979-986. 10.2174/138161208784139684.
Hochtl T, Tentzeris I, Schror K, et al: Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. Fundam Clin Pharmacol. 2011, [Epub ahead of print]
Toyama K, Sugiyama S, Oka H, et al: Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Atherosclerosis. 2011, 217: 158-164. 10.1016/j.atherosclerosis.2011.02.050.
Takayama T, Hiro T, Yamagishi M, et al: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009, 73: 2110-2117. 10.1253/circj.CJ-09-0358.
Semenova AE, Sergienko IV, Masenko VP, et al: The influence of rosuvastatin and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients. Acta Cardiol. 2009, 64: 405-409. 10.2143/AC.64.3.2038029.
Parakh N, Bhargava B: Rate control with ivabradine: angina pectoris and beyond. Am J Cardiovasc Drugs. 2011, 11: 1-12. 10.2165/11584840-000000000-00000.
Ferrari R, Guardigli G, Ceconi C: Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Cardiovasc Drugs Ther. 2010, 24: 331-339. 10.1007/s10557-010-6244-x.
De Ferrari GM, Leonardi S, Baduena L: Patients with acute coronary syndrome and nonobstructive coronary artery disease in the real world are markedly undertreated. J Cardiovasc Med. 2011, 12: 700-708. 10.2459/JCM.0b013e328348e575.
Bhupathiraju SN, Tucker KL: Coronary heart disease prevention: nutrients, foods, and dietry patterns. Clin Chim Acta. 2011, 412: 1493-1514. 10.1016/j.cca.2011.04.038.
Shukla SK, Gupta S, Ojha SK: Cardiovascular friendly natural products: a promising approach in the management of CVD. Nat Prod Res. 2010, 24: 873-898. 10.1080/14786410903417378.
Alherbish A, Charrois TL, Ackman ML, et al: The prevalence of natural health product use in patients with acute cardiovascular disease. PLoS One. 2011, 6: 19623-10.1371/journal.pone.0019623.
Pase MP, Grima NA, Sarris J: The effects of dietry and nutrient interventions on arterial stiffness: a systematic review. Am J Clin Nutr. 2011, 93: 446-454. 10.3945/ajcn.110.002725.
Morihara N, Hayama M, Fujii H: Aged garlic extract scavanges superoxide radicals. Plant Foods Hum Nutr. 2011, 66: 17-21. 10.1007/s11130-011-0216-6.
Borek C: Garlic reduces dementia and heart-disease risk. J Nutr. 2006, 136: 810-812.
Morihara N, Ide N, Weiss N: Aged garlic extract inhibits homocysteine-induced scavenger receptor CD36 expression and oxidized low-density lipoprotein cholesterol uptake in human macrophages in vitro. J Ethnopharmacol. 2011, 134: 711-716. 10.1016/j.jep.2011.01.021.
Kim HK, Choi YW, Lee EN, et al: 5-hydroxymethylfurfural from black garlic extract prevents TNFα-induced monocyte cell adhesion to HUVECs by suppression of vascular cell adhesion molecule-1 expression, reactive oxygen species generation and NF-κB activation. Phytother Res. 2011, [Epub ahead of print]
Lee EN, Choi YW, Kim HK, et al: Chloroform extract of aged black garlic attenuates TNF-α-induced ROS generation, VCAM expression, NF-κB activation and adhesiveness for monocytes in human umbilical vein endothelial cells. Phytother Res. 2011, 25: 92-100. 10.1002/ptr.3230.
Berginc K, Zakelj S, Kristi A: In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur J Nutr. 2010, 49: 373-384. 10.1007/s00394-010-0095-x.
Budoff MJ, Ahmadi N, Gul KM, et al: Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomised clinical trial. Prev Med. 2009, 49: 101-107. 10.1016/j.ypmed.2009.06.018.
Ried K, Frank OR, Stocks NP: Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial. Maturitas. 2010, 67: 144-150. 10.1016/j.maturitas.2010.06.001.
Ahmad MS, Ahmed N: Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. J Nutr. 2006, 136: 796-799.
Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA: RAGE biology, atherosclerosis and diabetes. Clin Sci. 2011, 121: 43-55. 10.1042/CS20100501.
Park S, Yoon SJ, Tae HJ, et al: RAGE and cardiovascular disease. Front Biosci. 2011, 16: 486-497. 10.2741/3700.
Lu Y, Qin W, Shen T, et al: The antioxidant N-Acetylcysteine promotes atherosclerotic plaque stabilization through suppression of RAGE, MMPs and NF-κB in ApoE-deficient mice. J Atheroscler Thromb. 2011, [Epub ahead of print]
Csiszar A: Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann N Y Acad Sci. 2011, 1215: 117-122. 10.1111/j.1749-6632.2010.05848.x.
Lippi G, Franchini M, Favaloro , et al: Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. Semin Thromb Hemost. 2010, 36: 59-70. 10.1055/s-0030-1248725.
Balestrieri ML, Schiano C, Felice , et al: Effect of low doses of red wine and pure resveratrol on circulating endothelial progenitor cells. J Biochem. 2008, 143: 179-186.
Yang J, Wang N, Zhu Y, et al: Roles of SIRT! In high glucose-induced endothelial impairment: association with diabetic atherosclerosis. Arch Med Res. 2011, [Epub ahead of print]
Lin KH, Hsiao G, Shih CM, et al: Mechanisms of resveratrol-induced platelet apoptosis. Cardiovasc Res. 2009, 83: 575-585. 10.1093/cvr/cvp139.
Cicha I, Regler M, Urschel K, et al: Resveratrol inhibits monocyte cell chemotaxix to MCP-1 and prevents spontaneous endothelial cell migration through Rho kinase-dependent mechanism. J Atheroscler Thromb. 2011, [Epub ahead of print]
Tsai YF, Liu FC, Lau YT, et al: Role of Akt-dependent pathway in resveratrol-mediated cardioprotection after trauma-hemorrhage. J Surg Res. 2011, [Epub ahead of print]
Kang OH, Jang HJ, Chae HS, et al: Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles in NF-kappaB and MAPK. Pharmacol Res. 2009, 59: 330-337. 10.1016/j.phrs.2009.01.009.
Norata GD, Marchesi P, Passamonti S, et al: Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis. 2007, 191: 265-271. 10.1016/j.atherosclerosis.2006.05.047.
Kim JW, Lim SC, Lee MY, et al: Inhibition of neointimal formation by trans-resveratrol: role of phosphatidyl inositol 3-kinase-dependent Nrf2 activation in heme oxygenase-1 induction. Mol Nutr Food Res. 2010, 54: 1497-1505. 10.1002/mnfr.201000016.
Brito PM, Devillard R, Negre-Salvayre A, et al: Resveratrol inhibits mTOR mitogenic signalling evoked by oxidized LDL in smooth muscle cells. Atherosclerosis. 2009, 205: 126-134. 10.1016/j.atherosclerosis.2008.11.011.
Takahashi S, Nakashima Y: Repeated and long-term treatment with physiologic concentrations of resveratrol promotes NO production in vascular endothelial cells. Br J Nutr. 2011, [Epub ahead of print]
Yun JM, Chien A, Jialal I, et al: Resveratrol up-regulates SIRT-1 and inhibits cellular oxidative stress in the diabetic milieu : mechanistic insights. J Nutr Biochem. 2011, [Epub ahead of print]
Arrick DM, Sun H, Patel KP, et al: Chronic resveratrol treatment restores vascular responsiveness of cerebral arterioles in type 1 diabetic rats. Am J Physiol Heart Circ Physiol. 2011, 301: 696-703. 10.1152/ajpheart.00312.2011.
Gkaliagakousi E, Ferro A: Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front Biosci. 2011, 16: 1873-1897. 10.2741/3828.
Kovacic P, Somanathan R: Multifaceted approach to resveratrol bioactivity: focus on anti-oxidant action, cell signalling and safety. Oxid Med Cell Longev. 2010, 3: 86-100. 10.4161/oxim.3.2.11147.
Juhasz B, Das DK, Kertesz A, et al: Reduction of blood cholesterol and ischaemic injury in the hypercholesteromic rabbits with modified resveratrol, longevinex [corrected]. Mol Cell Biochem. 2011, 348: 199-203. 10.1007/s11010-010-0615-2.
Robich MP, Osipov RM, Chu LM, et al: Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischaemia. Eur J Pharmacol. 2011, 664: 45-53. 10.1016/j.ejphar.2011.04.059.
Chen CJ, Yu W, Fu YC, et al: Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun. 2009, 378: 389-393. 10.1016/j.bbrc.2008.11.110.
Chacko SM, Thambi PT, Kuttan R, et al: Beneficial effects of green tea: a literature review. Indian J Gastroenterol. 2010, 30: 118-127.
Hsu SP, Wu MS, Yang CC, et al: Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hyperchlorous acid, atherosclerotic factors, and pro-inflammatory cytokines. Am J Clin Nutr. 2007, 86: 1539-1547.
Hodgson JM, Croft KD: Tea flavonoids and cardiovascular health. Mol Aspects Med. 2010, 31: 495-502. 10.1016/j.mam.2010.09.004.
Kuriyama S: The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies. J Nutr. 2008, 138: 1548-1553.
Ras RT, Zock PL, Draijer R: Tea consumption enhances endothelial-dependent vasodilation: a meta-analysis. PLoS One. 2011, 6: 16974-10.1371/journal.pone.0016974.
Tinahones FJ, Rubio MA, Garrido-Sanchez L, et al: Green tea reduces oxidability and improves vascular function. J Am Col Nutr. 2008, 27: 209-213.
Sabu MC, Smitha K, Kuttan R: Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. J Ethnopharmacol. 2002, 83: 109-116. 10.1016/S0378-8741(02)00217-9.
Kobayashi Y, Suzuki M, Satsua H: Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. J Agric Food Chem. 2000, 48: 5618-5623. 10.1021/jf0006832.
Liu J, Ying C, Meng Y, et al: Green tea polyphenols inhibit plasminogen activator inhibitor-1 expression and secretion in endothelial cells. Blood Coagul Fibrinolysis. 2009, 20: 552-557. 10.1097/MBC.0b013e32832e05f0.
Hininger-Favier I, Benaraba R, Coves S, et al: Green tea extract decreases oxidative stress and improves insulin sensitivity in an animal model of insulin resistance, the fructose fed rat. J Am Coll Nutr. 2009, 28: 355-361.
Baile CA, Yang YJ, Rayalam S, et al: Effect of resveratrol on fat mobilization. Ann NY Acad Sci. 2011, 1215: 40-47. 10.1111/j.1749-6632.2010.05845.x.
Hollman PC, Cassidy A, Comte B, et al: The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. J Nutr. 2011, 141: 989-1009. 10.3945/jn.110.131490.
Smoliga JM, Vanf O, Baur JA: Challenges of translating basic research into therapeutics: resveratrol as an example. J Gerentol A Biol Sci Med Sci. 2011, [Epub ahead of print]
Schmidt M, Schmitz HJ, Baumgart A, et al: Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food Chem Toxicol. 2005, 43: 307-314. 10.1016/j.fct.2004.11.001.
Yun SY, Kim SP, Song DK: Effects of (−)-epigallocatechin-3-gallate on pancreatic beta-cell damage in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2006, 541: 115-121. 10.1016/j.ejphar.2006.04.040.